Drug intelligence / Profile preview

PF2020-CELL

Development stage: Phase 1
Lead developer: CryoCord
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

PF2020-CELL is an allogeneic cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells (UC-MSCs). Developed by the Malaysian biotechnology company CryoCord, it is being investigated for the treatment of complex perianal fistulas in patients with Crohn's disease. Mesenchymal stem cells are known for their immunomodulatory and anti-inflammatory properties, which are thought to promote tissue repair and the closure of fistulous tracts by modulating the local immune environment and stimulating re-epithelialization. In clinical trials, PF2020-CELL is administered via local injection directly into the tissue surrounding the fistula.

Other names: allogeneic human umbilical cord mesenchymal stem cellsUC-MSCs

Beyond the preview

Go deeper on PF2020-CELL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF2020-CELL.

Explore the full profile